BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11376111)

  • 1. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
    Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
    Ghali SA; Gottlieb B; Lumbroso R; Beitel LK; Elhaji Y; Wu J; Pinsky L; Trifiro MA
    J Clin Endocrinol Metab; 2003 May; 88(5):2185-93. PubMed ID: 12727974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
    Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
    Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
    Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
    Zhou ZX; He B; Hall SH; Wilson EM; French FS
    Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.
    Elhaji YA; Wu JH; Gottlieb B; Beitel LK; Alvarado C; Batist G; Trifiro MA
    Mol Endocrinol; 2004 Aug; 18(8):1876-86. PubMed ID: 15118070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype.
    Tadokoro R; Bunch T; Schwabe JW; Hughes IA; Murphy JC
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):253-60. PubMed ID: 19178528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors.
    Slagsvold T; Kraus I; Bentzen T; Palvimo J; Saatcioglu F
    Mol Endocrinol; 2000 Oct; 14(10):1603-17. PubMed ID: 11043576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A G577R mutation in the human AR P box results in selective decreases in DNA binding and in partial androgen insensitivity syndrome.
    Nguyen D; Steinberg SV; Rouault E; Chagnon S; Gottlieb B; Pinsky L; Trifiro M; Mader S
    Mol Endocrinol; 2001 Oct; 15(10):1790-802. PubMed ID: 11579211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five novel androgen receptor gene mutations associated with complete androgen insensitivity syndrome.
    Jääskeläinen J; Mongan NP; Harland S; Hughes IA
    Hum Mutat; 2006 Mar; 27(3):291. PubMed ID: 16470553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions.
    Ghadessy FJ; Lim J; Abdullah AA; Panet-Raymond V; Choo CK; Lumbroso R; Tut TG; Gottlieb B; Pinsky L; Trifiro MA; Yong EL
    J Clin Invest; 1999 Jun; 103(11):1517-25. PubMed ID: 10359561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the amino-terminal domain of the human androgen receptor may be associated with partial androgen insensitivity and impaired transactivation in vitro.
    Holterhus PM; Werner R; Struve D; Hauffa BP; Schroeder C; Hiort O
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):457-63. PubMed ID: 16151980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions.
    Black BE; Vitto MJ; Gioeli D; Spencer A; Afshar N; Conaway MR; Weber MJ; Paschal BM
    Mol Endocrinol; 2004 Apr; 18(4):834-50. PubMed ID: 14684849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
    Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
    Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
    Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
    Jääskeläinen J; Deeb A; Schwabe JW; Mongan NP; Martin H; Hughes IA
    J Mol Endocrinol; 2006 Apr; 36(2):361-8. PubMed ID: 16595706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.